Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis

Barabanshchikova, MV; Морозова, Е. В.; Baykov, V.; Barkhatov, I. M.; Мамаев, Н Н; Bondarenko, SN; Alyanskii, AL; Zubarovskaya, L. S.; Афанасьев, Б. В.

doi:10.21320/2500-2139-2016-9-3-279-286

Cited by 2 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Это значительно ухудшает результаты терапии и требует разработки и внедрения новых протоколов подготовки пациентов с ПмФ к аллотГСК. [1,23,[25][26][27][28][29].…”

Section: предпосылки применения руксолитиниба в качестве подготовки к...unclassified

“…Спленэктомия и облучение селезенки, использовавшиеся раннее с целью уменьшения неблагоприятного влияния спленомегалии на исход аллотГСК, сопровождаются риском развития различных осложнений (инфекции, тромбозы, кровотечения) [25,30,31,32]. терапия руксолитинибом, в этом случае, представляет собой самый безопасный способ уменьшения размера селезенки.…”

Section: предпосылки применения руксолитиниба в качестве подготовки к...unclassified

See 1 more Smart Citation

POSSIBILITIES OF USING RUXOLITINIB TO IMPROVE THE RESULTS OF allo-HSCT (LITERATURE REVIEW)

Gribkova¹,

Ishmatova²,

Davydovskaya³

et al. 2019

Problems in oncology

View full text Add to dashboard Cite

The aim of the study was to systematize and summarize the current available data on ruxolitinib use in patients with myelofibrosis (MF) prior to allogeneic hematopoietic stem cell transplantation (allo-HSCT) to improve its results. The review includes data from foreign and domestic articles found in the PubMed and elibrary.ru databases describing the results of the use of ruxolitinib in patients with MF prior to allo-HSCT, including clinical cases, original scientific studies and reviews. It is reported that ruxolitinib therapy is safe, reduces mortality in the early post-transplantation period, reduces the incidence of acute and chronic graft-versus-host disease, and decreases the frequency of relapses. Clinical improvement with ruxolitinib therapy prior to allo-HSCT can be considered a prognostically favorable factor.

show abstract

Section: предпосылки применения руксолитиниба в качестве подготовки к...unclassified

POSSIBILITIES OF USING RUXOLITINIB TO IMPROVE THE RESULTS OF allo-HSCT (LITERATURE REVIEW)

Gribkova¹,

Ishmatova²,

Davydovskaya³

et al. 2019

Problems in oncology

View full text Add to dashboard Cite

show abstract

“…В связи с высоким риском развития осложнений, выполнение алло-ТГСК при ПМФ рекомендовано только больным, относящимся к группам промежуточного или высокого риска по критериям DIPSS-plus; MIPSS70-plus [7][8][9]. Существуют лишь единичные работы, в которых отражена динамика изменений КМ больных ПМФ до и после выполнения алло-ТГСК [10].…”

Section: Introductionunclassified

Comparative characteristics of bone marrow cell composition, stroma, and trabecular bone in allogenic hematopoietic stem cell transplantation in patients with primary myelofibrosis

Chebotarev¹,

Ковригина²,

Меликян³

et al. 2021

Gematologiâ i transfuziologiâ

View full text Add to dashboard Cite

Introduction. Primary myelofibrosis (PMF) is a clonal disease violating the cell composition, histological topography and stroma in bone marrow (BM). Allogeneic haematopoietic stem cell transplantation (allo-HSCT) is a curative therapy in PMF.Aim — description of change in the haematopoietic tissue cell composition and stroma, as well as in trabecular bone in allo-HSCT patients with fibrotic PMF.Materials and methods. We studies 24 trephine biopsy samples from nine PMF patients with allo-HSCT at the intervals: I — 1 month prior to, II — past 1–3 months and III — past 4–6 months from allo-HSCT. BM trephine biopsy slides were prepared in a standard histological assay with haematoxylin—eosin and additional staining with Gomori’s silver and Masson’s trichrome. Morphological change was evaluated in reticulin and collagen stroma, bone trabeculae, cellularity and topography of haematopoietic tissue.Results. The BM trephine biopsies of interval I were morphologically distinguished in three types by haematopoietic cellularity, stromal and trabecular sclerotic change. Post-transplant intervals II and III (3–6 months after allo-HSCT) did not reveal these types but showed an evident myelofibrosis and osteosclerosis reduction and signs of a restoring bone remodelling cycle. Myelopoietic lineages recovered in stages: the erythroid germ restored in three, granulocytic — in six months, and megakaryocytic cellularity did not fully recover in six months. Myelopoietic cellularity recovery outpaced blood recovery, which may be due to induced myelodysplasia or disruption of stromal niches.Conclusion. Allo-HSCT leads to the disappearance of PMF-pathognomonic BM morphology reflecting a histological remission. The reduction of myelofibrosis and osteosclerosis and normalisation of the trabecular bone remodelling cycle in post-transplant periods indicates an impact of cell microenvironment on PMF pathogenesis and warrants research into the composition and histological topography of cell microenvironment in PMF.

show abstract

Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis

Cited by 2 publications

References 19 publications

POSSIBILITIES OF USING RUXOLITINIB TO IMPROVE THE RESULTS OF allo-HSCT (LITERATURE REVIEW)

POSSIBILITIES OF USING RUXOLITINIB TO IMPROVE THE RESULTS OF allo-HSCT (LITERATURE REVIEW)

Comparative characteristics of bone marrow cell composition, stroma, and trabecular bone in allogenic hematopoietic stem cell transplantation in patients with primary myelofibrosis

Contact Info

Product

Resources

About